Chest Medicine (all articles)
RCT: Awake prone positioning reduces the need for intubation in patients with COVID-19.
23 Aug, 2021 | 00:03h | UTCInvited commentary: Awake prone positioning in COVID-19: is tummy time ready for prime time?
Related:
Commentary on Twitter
Awake prone positioning of pts w/ hypoxaemic respiratory failure due to #COVID19 reduces incidence of treatment failure & need for intubation w/o any signal of harm
Meta-trial from the Awake Prone Positioning Meta-Trial Group https://t.co/GuDdjPnVps pic.twitter.com/ZS08uQN1gE
— The Lancet Respiratory Medicine (@LancetRespirMed) August 21, 2021
Evidence mounts that people with breakthrough infections can spread Delta easily.
22 Aug, 2021 | 23:57h | UTCOriginal study: Shedding of Infectious SARS-CoV-2 Despite Vaccination when the Delta Variant is Prevalent – Wisconsin, July 2021 – medRxiv
Commentary on Twitter
The evidence that supports Delta breakthrough infections ability to spread (and why fully vaccinated people need to ? up)https://t.co/27NOf6mYCM @NatGeo by @Ecquis w/ studies and input by @GuptaR_lab and @KasenRiemersma
— Eric Topol (@EricTopol) August 20, 2021
Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.
22 Aug, 2021 | 23:51h | UTCInvited Commentary: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
Related:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)
Commentary on Twitter
NEW Research—Heterologous ChAdOx1 nCov-19–BNT162b2 immunisation w/ 10–12-week interval is well tolerated & improves immunogenicity vs homologous ChAdOx1 nCov-19 vax w/ 10–12-week interval & BNT162b2 vax w/ 3-week interval
Study from Prof Sander & co https://t.co/VAB54NokSi pic.twitter.com/wfeBsvoKhO
— The Lancet Respiratory Medicine (@LancetRespirMed) August 13, 2021
Study Commentaries: Non-invasive ventilation for COVID 19 patients. The Recovery RS trial.
22 Aug, 2021 | 23:52h | UTCCommentary 1: JC: Non-invasive ventilation for COVID 19 patients. The Recovery RS trial – St Emlyn’s
NICE Guideline: Obstructive sleep apnea/hypopnea syndrome and obesity hypoventilation syndrome in over 16s.
22 Aug, 2021 | 23:10h | UTC
Study: Macrolide use significantly associated with both prevalent and incident tinnitus.
22 Aug, 2021 | 22:11h | UTCCommentary: Macrolide Use and Tinnitus: A New Safety Ringtone? – NEJM Journal Watch (free for a limited period)
[Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.
20 Aug, 2021 | 10:03h | UTCCommentaries:
Pfizer vaccine effectiveness declines faster than AstraZeneca – study – Evening Standard
Commentary on Twitter
New large UK study confirms attrition of @Pfizer vaccine effectiveness vs Delta infections over time https://t.co/K6YRyAQq4o "By roughly 4 1/2 months after the 2nd dose, Pfizer’s shot will probably be about on par with Astra’s at preventing infections with a high viral burden" pic.twitter.com/x1Nl2BkWfn
— Eric Topol (@EricTopol) August 19, 2021
Covid-19: How many variants are there, and what do we know about them?
20 Aug, 2021 | 10:00h | UTCCovid-19: How many variants are there, and what do we know about them? – The BMJ
Commentary on Twitter
Eight notable variants of SARS-CoV-2 have been found since September 2020. @emahase_ reviews the line-up so far https://t.co/jmzfnbudoL
Watch this video showing how the variants have spread around the globe: pic.twitter.com/KwBl6B48Dy
— The BMJ (@bmj_latest) August 19, 2021
New SARS-CoV-2 variants have changed the pandemic. What will the virus do next?
20 Aug, 2021 | 09:58h | UTCNew SARS-CoV-2 variants have changed the pandemic. What will the virus do next? – Science
Commentary on Twitter
I really, really wish Covid deniers and minimizers would read this outstanding @ScienceMagazine piece by @kakape on the delta variant and how it has completely changed this pandemic – FOR THE WORSEhttps://t.co/liIC9NpGOJ pic.twitter.com/UkCieUUCpK
— Madhu Pai, MD, PhD (@paimadhu) August 19, 2021
A grim warning from Israel: Vaccination blunts, but does not defeat Delta.
20 Aug, 2021 | 09:56h | UTCA grim warning from Israel: Vaccination blunts, but does not defeat Delta – Science
Delta’s rise is fuelled by rampant spread from people who feel fine.
20 Aug, 2021 | 09:54h | UTCDelta’s rise is fuelled by rampant spread from people who feel fine – Nature
Original study: Transmission dynamics and epidemiological characteristics of Delta variant infections in China – medRxiv
Post-Covid-19 Tachycardia Syndrome: A distinct phenotype of Post-acute Covid-19 Syndrome.
20 Aug, 2021 | 09:51h | UTC
Commentary on Twitter
Post-COVID19 tachycardia syndrome(s): nice proposal for phenotypeshttps://t.co/XI75HCGYUH pic.twitter.com/yg303QXd1E
— Otavio Ranzani (@otavio_ranzani) August 18, 2021
Long COVID-19: A Primer for Cardiovascular Health Professionals, on Behalf of the CCS Rapid Response Team.
20 Aug, 2021 | 09:49h | UTC
M-A: Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation.
20 Aug, 2021 | 09:01h | UTCPrevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients – European Heart Journal (link to abstract – $ for full-text)
Commentary on Twitter
AF-COMET Meta-analysis showed #COPD is common in #AF, being found in 13% of patients
?⬆️ burden of comorbidities & worse outcomes
?More than a two-fold ⬆️ risk of all-cause death
?⬆️ Risk of CV death and major bleedinghttps://t.co/fLAuGkQAX1 @ESC_Journals @SchakrabartiEP pic.twitter.com/50OSfACH84— Henry Han, MBBS, MD (@HanCardiomd) August 2, 2021
Review: Viral respiratory pathogens and lung injury.
20 Aug, 2021 | 08:43h | UTCViral Respiratory Pathogens and Lung Injury – Clinical Microbiology Reviews
IDSA response to plan for supplemental vaccine doses for vaccinated individuals.
19 Aug, 2021 | 09:02h | UTC
Viewpoint: Confronting the Delta variant of SARS-CoV-2.
19 Aug, 2021 | 09:03h | UTCConfronting the Delta Variant of SARS-CoV-2, Summer 2021 – JAMA
Studies: COVID vaccine protection waning against infection but not hospitalization.
19 Aug, 2021 | 09:05h | UTCStudies: COVID vaccine protection waning against infection but not hospitalization – CIDRAP
Commentary on Twitter (thread – click for more)
Very excited to share our most recent publication about #CovidVaccine effectiveness, just published today by the IVY network. Especially relevant in light of today’s news about #boosters (spoiler – I’m skeptical about the need for boosters for all). ?https://t.co/GbAxgzpo7R
— Nida Qadir, MD (@NidaQadirMD) August 18, 2021
NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.
19 Aug, 2021 | 09:06h | UTCOriginal study: Early Convalescent Plasma for High-Risk Outpatients with Covid-19 – New England Journal of Medicine
Commentary on Twitter
Convalescent plasma did not prevent disease progression in patients seen in EDs within 7 days after the onset #COVID19 symptoms. https://t.co/9gmIK3ntKH #IDTwitter pic.twitter.com/sirzn1uGL0
— NEJM (@NEJM) August 18, 2021
U.S. officials’ decision on Covid-19 booster shots baffles — and upsets — some scientists.
19 Aug, 2021 | 09:00h | UTCU.S. officials’ decision on Covid-19 booster shots baffles — and upsets — some scientists – STAT
Commentary on Twitter
Scientists I spoke to today had a lot of questions about the administration's decision to start giving Americans 3rd doses of the mRNA vaccines next month. “I’m not sure we had enough [data] to pull the trigger right now," one said. https://t.co/eHUndOrQL4
— Helen Branswell (@HelenBranswell) August 18, 2021
Review: CT of postacute lung complications of COVID-19.
19 Aug, 2021 | 08:55h | UTCCT of Postacute Lung Complications of COVID-19 – Radiology
Related:
Fibrotic interstitial lung abnormalities at 1-year follow-up CT after severe COVID-19.
Postacute Sequelae of COVID-19 Pneumonia: 6-month Chest CT Follow-up.
COVID-19 Imaging: What we know now and what remains unknown.
Post severe COVID-19, CT reveals potentially lifetime lung damage in one-thirds of patients
COVID-19 mimics on chest CT: a pictorial review and radiologic guide
Review: Interstitial Lung Abnormalities.
19 Aug, 2021 | 08:37h | UTCInterstitial Lung Abnormalities: State of the Art – Radiology
Surgery for lung cancer: postoperative changes and complications—what the Radiologist needs to know.
19 Aug, 2021 | 08:36h | UTC
Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.
18 Aug, 2021 | 09:04h | UTCRelated:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)
Commentary on Twitter (thread – click for more)
Mix and match vaccines, AZ then mRNA (@BioNTech_Group) achieves a very strong immune response against the Delta variant.
This is the 1st report to look at mix vs Delta, specifically.https://t.co/6N46cUh8HW @TheLancet pic.twitter.com/cvlHp2XtXJ— Eric Topol (@EricTopol) August 17, 2021
U.S. to recommend COVID vaccine boosters at 8 months.
18 Aug, 2021 | 09:02h | UTCSources: US to recommend COVID vaccine boosters at 8 months – Associated Press
See also: Biden administration expected to advise Covid booster shots for most Americans – CNN AND US experts expected to recommend Covid booster shots for all – The Guardian
Commentary on Twitter (thread – click for more)
This decision seems to reflect a common fallacy; trying to reason about whether we "need X" just based on what things are like without X, rather than how much X will do to help.
It's surprising to see it at play in a decision of such consequence.
— Wes Pegden (@WesPegden) August 17, 2021